These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
278 related items for PubMed ID: 24254559
21. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells. Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T. Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368 [Abstract] [Full Text] [Related]
22. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice. Lin QY, Wang YF, Weng HN, Sheng XJ, Jiang QP, Yang ZY. J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082 [Abstract] [Full Text] [Related]
26. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis. Zhao J, Chen X, Lin W, Wu G, Zhuang Q, Zhong X, Hong Z, Peng J. Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043 [Abstract] [Full Text] [Related]
27. Intratumoral delivery of paclitaxel using a thermosensitive hydrogel in human tumor xenografts. Kim JH, Lee JH, Kim KS, Na K, Song SC, Lee J, Kuh HJ. Arch Pharm Res; 2013 Jan; 36(1):94-101. PubMed ID: 23371803 [Abstract] [Full Text] [Related]
29. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer. Faria RS, de Lima LI, Bonadio RS, Longo JPF, Roque MC, de Matos Neto JN, Moya SE, de Oliveira MC, Azevedo RB. Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249 [Abstract] [Full Text] [Related]
30. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]. Song Y, Shen K, Tang PP. Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904 [Abstract] [Full Text] [Related]
31. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction. Xiong XY, Guo L, Gong YC, Li ZL, Li YP, Liu ZY, Zhou M. Eur J Pharm Sci; 2012 Aug 15; 46(5):537-44. PubMed ID: 22538053 [Abstract] [Full Text] [Related]
32. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. Ye L, He J, Hu Z, Dong Q, Wang H, Fu F, Tian J. Food Chem Toxicol; 2013 Feb 15; 52():200-6. PubMed ID: 23149094 [Abstract] [Full Text] [Related]
33. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R. Int J Cancer; 2018 Nov 01; 143(9):2187-2199. PubMed ID: 29752717 [Abstract] [Full Text] [Related]
34. [Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus]. Jiang HY, Feng YJ. Zhonghua Fu Chan Ke Za Zhi; 2004 Jul 01; 39(7):474-7. PubMed ID: 15347472 [Abstract] [Full Text] [Related]
35. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Cancer Epidemiol Biomarkers Prev; 2003 Sep 01; 12(9):933-9. PubMed ID: 14504208 [Abstract] [Full Text] [Related]
36. [Regulative effect of genistein on xenografted tumor of ovarian carcinoma cell on nude mice]. Wang X, Xin XY, Huang YH. Zhongguo Zhong Yao Za Zhi; 2006 Jun 01; 31(11):901-4. PubMed ID: 17048629 [Abstract] [Full Text] [Related]
37. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells. Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M. Cancer Res; 2004 Oct 15; 64(20):7526-32. PubMed ID: 15492279 [Abstract] [Full Text] [Related]
38. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R. Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869 [Abstract] [Full Text] [Related]
39. [Technetium-99m labeled synaptotagmin I C2A detection of paclitaxel-induced apoptosis in non-small cell lung cancer]. Wang F, Fang W, Ji SD, Meng QL, Li Y, Fan KW, Wang ZZ. Zhonghua Zhong Liu Za Zhi; 2007 May 15; 29(5):351-4. PubMed ID: 17892130 [Abstract] [Full Text] [Related]
40. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V. Biochem J; 2006 Apr 15; 395(2):311-8. PubMed ID: 16356169 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]